Teladoc Inc (TDOC) Receives $51.00 Consensus Price Target from Analysts

Teladoc Inc (NYSE:TDOC) has been given a consensus rating of “Buy” by the twenty-two analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, fourteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $51.00.

TDOC has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $35.00 target price (up from $31.00) on shares of Teladoc in a research report on Tuesday, February 27th. Chardan Capital reaffirmed a “buy” rating and issued a $47.00 target price (down from $48.00) on shares of Teladoc in a research report on Wednesday, February 28th. Canaccord Genuity increased their target price on Teladoc from $43.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Deutsche Bank increased their target price on Teladoc to $45.00 and gave the stock a “buy” rating in a research report on Friday, March 2nd. Finally, KeyCorp reaffirmed an “overweight” rating and issued a $50.00 target price (up from $41.00) on shares of Teladoc in a research report on Thursday, March 15th.

In other news, CEO Jason N. Gorevic sold 25,000 shares of the firm’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $41.36, for a total transaction of $1,034,000.00. Following the transaction, the chief executive officer now directly owns 661,184 shares of the company’s stock, valued at $27,346,570.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Mark Hirschhorn sold 69,460 shares of the firm’s stock in a transaction on Wednesday, May 2nd. The shares were sold at an average price of $43.73, for a total value of $3,037,485.80. Following the transaction, the vice president now directly owns 50,042 shares in the company, valued at $2,188,336.66. The disclosure for this sale can be found here. Insiders have sold 119,460 shares of company stock worth $5,294,736 over the last three months. Corporate insiders own 3.95% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Teladoc by 68.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock valued at $116,000 after buying an additional 1,171 shares in the last quarter. Swiss National Bank boosted its stake in Teladoc by 1.7% during the first quarter. Swiss National Bank now owns 94,400 shares of the health services provider’s stock valued at $3,804,000 after buying an additional 1,600 shares in the last quarter. LPL Financial LLC boosted its stake in Teladoc by 18.6% during the first quarter. LPL Financial LLC now owns 11,431 shares of the health services provider’s stock valued at $461,000 after buying an additional 1,791 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Teladoc by 4.8% during the first quarter. The Manufacturers Life Insurance Company now owns 42,984 shares of the health services provider’s stock valued at $1,732,000 after buying an additional 1,984 shares in the last quarter. Finally, We Are One Seven LLC boosted its stake in Teladoc by 241.1% during the first quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock valued at $115,000 after buying an additional 2,011 shares in the last quarter.

Teladoc traded up $0.65, hitting $54.25, during trading hours on Friday, according to MarketBeat.com. 8,191 shares of the stock were exchanged, compared to its average volume of 920,580. Teladoc has a 12 month low of $27.30 and a 12 month high of $55.95. The stock has a market capitalization of $3.34 billion, a PE ratio of -32.65 and a beta of 0.42. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.15 and a quick ratio of 4.15.

Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. The firm had revenue of $89.64 million for the quarter, compared to analysts’ expectations of $86.77 million. During the same period last year, the business posted ($0.30) earnings per share. The firm’s revenue for the quarter was up 109.0% on a year-over-year basis. research analysts anticipate that Teladoc will post -1.45 earnings per share for the current fiscal year.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply